3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Breast
4
Genitourinary
3
Thoracic
2
Sarcoma
2
Lymphoid
2
Gynecologic
2
Plasma cell
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Head & Neck
1
Endocrine
1
Dermatologic
1
Classical hematology
1
CNS
1
Conditions
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Brain Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Thyroid Cancer Patients Who Received Target Therapy
1
Interventions
selpercatinib
3
Fulvestrant
3
Fluorodeoxyglucose F18
3
ribociclib
2
Trastuzumab
2
Magnetic Resonance Spectroscopy
2
Letrozole
2
Cyclophosphamide
2
Alpelisib
2
vandetanib
1
tivozanib
1
tipifarnib
1
temsirolimus
1
romidepsin
1
pembrolizumab
1
gadoteridol
1
gadoterate meglumine
1
gadolinium ethoxybenzyl DTPA
1
gadodiamide
1
gadobutrol
1
gadobenic acid
1
fludarabine phosphate
1
fludarabine
1
exemestane
1
entrectinib
1
entinostat
1
avelumab
1
atezolizumab
1
alectinib
1
aldesleukin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
entrectinib
×
Endocrine
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA